Valink Therapeutics Raises $11.8M Pre‑A Round Led by Redalpine

Deal Summary

Cambridge-based Valink Therapeutics closed an $11.8M pre‑A financing to advance its bispecific antibody-drug conjugates and oncology programs. The round was led by redalpine with participation from LongeVC, Oxford Science Enterprises and existing backers RV Invest and p53 Invest.